The purpose of this registry is to obtain a general view as regards efficacy, tolerability and safety issues of the Torisel®, Sutent®, and/or Inlyta® therapies in patients with advanced renal cell carcinoma, recurrent / refractory mantle cell lymphoma (MCL) and gastro-intestinal stroma tumors (GIST) under the conditions of routine use
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Overall Survival (OS)
Timeframe: From initiation of treatment until the date of first documented progression or date of death from any cause, whichever came first, approximately 13 years and 10 months
Progression Free Survival (PFS)
Timeframe: From initiation of treatment until the date of first documented progression or date of death from any cause, whichever came first, approximately 13 years and 10 months
Number of Participants With Best Overall Response (BOR)
Timeframe: From initiation of treatment until the date of first documented progression or date of death from any cause, whichever came first, approximately 13 years and 10 months
Number of Participants Categorized According to Physician's Global Assessment of Effectiveness
Timeframe: From initiation of treatment until the date of first documented progression or date of death from any cause, whichever came first, approximately 13 years and 10 months
Karnofsky Performance Status (KPS) Scale
Timeframe: From initiation of treatment until the date of first documented progression or date of death from any cause, whichever came first, approximately 13 years and 10 months
Number of Participants Classified According to Eastern Cooperative Oncology Group (ECOG) Performance Status for Mantle Cell Lymphoma
Timeframe: From initiation of treatment until the date of first documented progression or date of death from any cause, whichever came first, approximately 13 years and 10 months
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Timeframe: From initiation of treatment until the date of first documented progression or date of death from any cause, whichever came first, approximately 13 years and 10 months
Number of Participants Who Discontinued Treatment Due to Adverse Events
Timeframe: From initiation of treatment until the date of first documented progression or date of death from any cause, whichever came first, approximately 13 years and 10 months
Number of Participants Categorized According to Physician's Global Tolerability Assessment
Timeframe: From initiation of treatment until the date of first documented progression or date of death from any cause, whichever came first, approximately 13 years and 10 months
Absolute Laboratory Values of Hematology Parameters: Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils and Hematocrit
Timeframe: Week 46 up to Week 55 post study inclusion
Absolute Laboratory Values of Hematology Parameters: Hemoglobin A1c (HbA1c)
Timeframe: Week 46 up to Week 55 post study inclusion
Absolute Laboratory Values of Hematology Parameters: Hemoglobin
Timeframe: Week 46 up to Week 55 post study inclusion
Absolute Laboratory Values of Clinical Chemistry Parameters: Calcium, Sodium, Potassium, Phosphate, Magnesium, Cholesterol, Triglycerides and Glucose
Timeframe: Week 46 up to Week 55 post study inclusion
Absolute Laboratory Values of Clinical Chemistry Parameters: Creatinine, Total Bilirubin
Timeframe: Week 46 up to Week 55 post study inclusion
Absolute Laboratory Values of Clinical Chemistry Parameters: Alanine Transaminase (ALT), Aspartate Transaminase (AST), Alkaline Phosphatase (ALP) and Lactate Dehydrogenase (LDH)
Timeframe: Week 46 up to Week 55 post study inclusion
Absolute Laboratory Values of Clinical Chemistry Parameters: Albumin
Timeframe: Week 46 up to Week 55 post study inclusion
Absolute Laboratory Values of Clinical Chemistry Parameters: Triiodothyronine (fT3) and Free Thyroxine (fT4)
Timeframe: Week 46 up to Week 55 post study inclusion
Absolute Laboratory Values of Clinical Chemistry Parameters: Thyroid Stimulating Hormone (TSH)
Timeframe: Week 46 up to Week 55 post study inclusion